Alerta

METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES

Resumen de: US2025073274A1

Provided are methods for treating a CD33-positive hematological malignancy, such as acute myelogenous leukemia or multiple myeloma, in a subject by administering to the subject hematopoietic stem cells (HSCs) or hematopoietic stem and progenitor cells (HSPCs) genetically modified to reduce or eliminate CD33 expression in myeloid cells derived therefrom in conjunction with antibody radioconjugates for one or both of conditioning the subject's bone marrow to receive and engraft the genetically modified stem cells and selectively depleting the subject's endogenous CD33-positive cells, including CD33-positive malignant cells.

DOSING REGIMENS FOR CANCER IMMUNOTHERAPY

Resumen de: US2025073266A1

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed/refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer.

COMBINATIONS OF LSD1 INHIBITORS FOR TREATING MYELOID CANCERS

Resumen de: US2025073232A1

The instant invention relates to combinations of LSD1 inhibitors (or pharmaceutically acceptable salts thereof) and gilteritinib (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating myeloid cancers, such as acute myeloid leukemia or myelodysplastic syndrome.

METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES

Resumen de: US2025073212A1

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

METHODS OF TREATING MULTIPLE MYELOMA USING BCL-2 INHIBITOR

Resumen de: AU2023309181A1

The present disclosure provides methods of treating multiple myeloma in a subject with a Bcl-2 inhibitor, in particularly 2- ( (1H-pyrrolo 2, 3-b pyridin-5-yl) oxy) -N- ( (4- ( ( ( (1r, 4r) -4-hydroxy-4-methylcyclohexyl) methyl) amino) -3-nitrophenyl) sulfonyl) -4- (2- ( (S) -2- (2-isopropylphenyl) pyrrolidin-1-yl) -7-azaspiro 3.5 nonan-7-yl) benzamide or a pharmaceutically acceptable salt thereof, or in combination with dexamethasone.

NOVEL DARPIN BASED CD70 ENGAGERS

Resumen de: US2025074994A1

The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD70. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g., acute myeloid leukemia (AML), in a mammal, including a human.

BISPECIFIC ANTIBODIES AND USES THEREOF

Resumen de: US2025074982A1

Provided herein are, inter alia, antibody compounds comprising an anti-immune cell antibody (e.g., anti-CD3 antibody) covalently bound to a CS-1-binding antibody; immune cells bound to compounds comprising an anti-immune cell antibody (e.g., anti-CD3 antibody) covalently bound to a CS-1-binding antibody; humanized OKT3 antibodies; pharmaceutical compositions; and methods for treating cancer, such as multiple myeloma.

CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS

Resumen de: US2025074890A1

Described are the compounds, compositions and methods of treating a disease or disorder characterized by aberrant B-cell lymphoma 6 (BCL6) activity.

ANTI-CD19 THERAPY IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF LEUKEMIA OR LYMPHOMA

Resumen de: US2025074979A1

The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survival and/or the progression free survival in patients having specific types of hematological cancer.

BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS

Resumen de: WO2025048759A1

The present invention pertains to benzimidazole derivatives of formula (I) and their inhibitory activity against mPGES-1. It also encompasses pharmaceutical compositions that include these benzimidazole derivatives and their application in treating mPGES-1-mediated diseases. The purpose of this invention is to create novel compounds that inhibit inducible mPGES-1, an enzyme responsible for catalyzing the final step in the biosynthesis of PGE2 from AA. These compounds are intended for the treatment of various inflammatory conditions, including but not limited to Parkinson's disease, autoimmune diseases, allergic disorders, rhinitis, coronary heart disease, ulcers, osteoarthritis, rheumatoid arthritis, systemic sclerosis, periodontitis, colon cancer, inflammatory bowel disease, cutaneous sclerosis, neuropathic pain, inflammation, pain, fever, migraine, chronic pain, acute pain, headache, asthma, pulmonary fibrosis, fibromyalgia, dysmenorrhea, atherosclerosis, gout, arthritis, rheumatic fever, multiple sclerosis, Hodgkin's disease.

TREATMENT OF NON SMALL CELL LUNG CANCER WITH ALECTINIB

Resumen de: WO2025045901A1

The present invention relates to a method of treating anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC), comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject has resected stage Ib ALK-positive NSCLC with a tumour greater or equal to 4cm to stage IIIa ALK-positive NSCLC.

REAGENTS AGAINST HUMAN ENDOGENOUS RETROVIRUSES TO TARGET CANCER CELLS

Resumen de: WO2025046393A1

The present invention relates to affinity reagents that are capable of specifically binding to a surface antigen of a virus belonging to the family of human endogenous retroviruses (HERV), in particular to a HERV envelope protein, for use in the prophylactic and/or therapeutic treatment of a cancer in a subject in need thereof. The invention relates also to the use of such affinity reagents in the diagnosis or prognosis of cancer, in particular lymphoma.

CHEMO-SENSITIVE DOMINANT CLONE FOR ADAPTIVE THERAPY

Resumen de: WO2025049877A1

Disclosed herein is a system that addresses all of the current challenges described above by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. Also disclosed herein is a 'Trojan-Horse' like genetic construct aimed at engineering a chemo-sensitive dominant clone for adaptive therapy in cancers, such as leukemia. In some embodiments, cells, such as cancer cells from a subject, are engineered with suicide genes to promote a bystander effect in neighboring cancer cells once returned to the subject. In some embodiments, these cells are further engineered to be clonally dominant, e.g. by deleting or mutating tumor suppressor genes in the cells, overexpressing oncogenes, or any combination thereof. Once the engineered cells have reached a target clonal dominance, the suicide gene can be induced, thereby promoting the bystander effect.

METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION

Resumen de: WO2025049966A2

Disclosed are methods of increasing R0R1 in a cell comprising administering an EZH2 inhibitor, G9A inhibitor, DNMT1 inhibitor or combination thereof to the cell. Disclosed are methods of treating lymphoma in a subject comprising administering to the subject one or more EZH2 inhibitors, G9A inhibitors, DNMT1 inhibitors or combinations thereof, wherein the one or more EZH2 inhibitors, G9A inhibitors, DNMT1 inhibitors or combinations thereof increase expression of R0R1 in one or more B cells in the subject; and one or more R0R1 targeting therapeutics.

MACROLIDE-NOX4 CONJUGATES AND USES THEREOF

Resumen de: WO2025049640A1

The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis), acute respiratory distress syndrome (ARDS) or for treating cancer (e.g., a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

SURVIVIN MRNA VACCINE

Resumen de: WO2025049442A1

Disclosed herein is an mRNA vaccine encoding a variant (double mutant form) of the survivin polypeptide and methods for treating a malignancy, such as myeloma, or for inducing an immune response, by administering the variant survivin mRNA vaccine. Also disclosed are methods for treating a malignancy using the disclosed mRNA vaccine.

NOX4 INHIBITORS AND METHODS OF USING SAME

Resumen de: WO2025049644A1

The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g, pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis), acute respiratory distress syndrome (ARDS), and cancer (e.g, a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

METHOD FOR QUANTIFYING NEOPLASTIC FOLLICULAR REGULATORY T CELLS AND NEOPLASTIC FOLLICULAR CYTOTOXIC T CELLS, METHOD FOR SCREENING NEOPLASTIC FOLLICULAR REGULATORY T CELLS AND NEOPLASTIC FOLLICULAR CYTOTOXIC T CELLS, THERAPEUTIC COMPOSITION, AND KIT

Resumen de: WO2025047660A1

The present invention provides a technology useful for predicting prognosis in a follicular lymphoma patient. The present invention is a method for quantifying neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject, in order to determine the prognosis of follicular lymphoma. The method comprises: a flow cytometry step in which neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject are detected and counted with flow cytometry using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD-1 antibody, an anti-CD25 antibody, and an anti-TIM-3 antibody; or a multiplex immunostaining step in which neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject are detected and counted with multiplex immunostaining using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD -1 antibody, an anti-FOXP3 antibody, an anti-TCF-1 antibody, and an anti-Granzyme K antibody.

IMMUNOSUPPRESSIVE COMPOUNDS

Resumen de: AU2023348356A1

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relates to a process for the stereoselective preparation of such compounds. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a vector comprising a coronin 1 promoter element, wherein in a vertebrate genome, said coronin 1 promoter element starts directly upstream from a transcription starting site (TSS) of a coronin 1 gene and spans a sequence stretch of at least about 700 bp in said genome. The present invention further relates to a method using said vector for identifying immunomodulatory compounds that alter the coronin 1 promoter activity. The present invention further relates to BRD3 as an upstream target responsible for driving the coronin-1 expression and activity in immune cells, and relates to compounds, in particular compound of formula (I), that selectively target bromodomains of BRD3 and thereby deplete coronin 1 levels.

RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N

Resumen de: EP4516300A2

Methods and compositions disclosed herein generally relate to compositions and methods for suppressing hematopoietic stem and progenitor cells (HSPCs) and the treatment of diseases or disorders involving UBE2N, such as cancers, including disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) and chronic inflammatory disorders. Particular aspects relate to treating, e.g. acute myelomonocytic leukemia (AML-M4) and acute monocytic leukemia (AML-M5). Particular aspects of the invention relate to determining an individual in need of treatment who can be treated with a UBE2N inhibitor, such as an individual having AML-M4 and/or AML-M5. The invention further relates to using a UBE2N inhibitor to treat a disease or disorder characterized by malignant hematopoietic cells, as well as other cancers, and chronic inflammatory disorders, and as immune checkpoint regulators.

BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND USES THEREOF

Resumen de: EP4516810A2

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.

METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF

Resumen de: AU2025200848A1

Abstract The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents. oc

INHIBITORS OF KRAS

Resumen de: US2025066386A1

Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.

METHODS OF TREATING CHRONIC MYELOID LEUKEMIA USING THE TYROSINE KINASE INHIBITOR VODOBATINIB

Resumen de: AU2023331249A1

The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of Formula 1 has been shown to be efficacious safe and tolerable at a dose from 10 mg to 210 mg.

ANTI-BCMA CAR T CELL COMPOSITIONS

Nº publicación: US2025064723A1 27/02/2025

Solicitante:

2SEVENTY BIO INC [US]
2seventy bio, Inc

Resumen de: US2025064723A1

The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed/refractory multiple myeloma.